08 Apr, 2020 09:58 AM
Melbourne, Australia, 8 April 2020: The merger of Sienna Cancer Diagnostics Ltd (“Sienna”, ASX:SDX)and BARD1 Life Sciences Limited (“BARD1”, ASX:BD1) will create a well-resou...read more
06 Dec, 2019 10:25 AM
Sienna Cancer Diagnostics Ltd (ASX:SDX) (“Sienna” or “the Company”), a medical technology company developing and commercialising innovative IVD tests, is pleased to announce ...read more
29 Nov, 2019 05:45 PM
The suspension of trading in the securities of Sienna Cancer Diagnostics Limited ('SDX') will be lifted immediately, following the release by SDX of an announcement regarding a capital raising...read more
29 Nov, 2019 05:43 PM
Sienna to raise up to approximately $4.2 million, before costs, via a share placement and rights issue at 3.5 cents per share.
To read more, download the attached PDF.
28 Nov, 2019 10:11 AM
The securities of Sienna Cancer Diagnostics Limited ('SDX') will be suspended from quotation immediately under Listing Rule 17.2, at the request of SDX, pending the release of an announcement ...read more
01 Nov, 2019 09:14 AM
Melbourne, Australia, 31 October 2019: Sienna Cancer Diagnostics Ltd, (ASX:SDX) (“Sienna” or “the Company”), a medical technology company developing and commercialising innovat...read more
16 Oct, 2019 05:18 PM
Matthew Hoskin will be stepping down from his role as Chief Executive Officer of the Company, and will be replaced by Carl Stubbings, currently a non-executive Director.
For more information, d...read more
23 Sep, 2019 01:52 PM
Melbourne, Australia, 23 September 2019: Sienna Cancer Diagnostics Ltd, (ASX:SDX) (“Sienna” or “the Company”), a medical technology company developing and commercialising innov...read more
01 Jul, 2019 05:14 PM
U.S. Patent No. 10,338,072 granted to Sienna by the United States Patent and Trademark Office
Provides patent protection for Sienna’s hTERT test to 2035
For more inf...read more
